Main Hero Image
About Us Icon

PMZ 2010 : Resuscitation of hypovolemic shock


  • PMZ-2010, a cardiovascular active agent, is highly effective in resuscitation of hypovolemic shock.
  • Potential global market size of about $10 billion.
  • Significantly reduced the mortality, decreased blood lactate, and increased mean arterial pressure, pulse pressure and cardiac output in hypovolemic shock.
  • Unique mechanism of action, it increases blood pressure, tissue perfusion and decreases work load on the heart.
  • Efficacy of PMZ-2010 has been demonstrated in (1) a rat model of fixed pressure blood loss, (2) rabbit model of uncontrolled bleeding with trauma, and (3) a pig model of massive blood loss.
  • Chemistry, manufacturing and controls for PMZ-2010 are complete.
  • Japan patent office has issued patent titled “Novel Therapeutic Treatments Using Centhaquin” Japan Patent No. 2012-508721.
  • China patent office has granted patent titled “Novel Therapeutic Treatments Using Centhaquin” China patent No. 201080029672.5.
  • Patents in other countries are pending.
  • Clinical stage – Phase I (CTRI/2014/06/004647) completed.
  • Link to publications